Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

NRPH

New River (NRPH)

New River Pharmaceuticals (MM)
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NRPH
DateTimeSourceHeadlineSymbolCompany
19/04/200706:41PR Newswire (US)HealthShares(TM) Announces Changes to the HealthShares(TM) Neuroscience and Composite IndicesNASDAQ:NRPHNew River Pharmaceuticals (MM)
03/04/200723:00PR Newswire (US)New River Pharmaceuticals Inc. Announces Convertibility of 3.50% Convertible Subordinated Notes Due 2013NASDAQ:NRPHNew River Pharmaceuticals (MM)
20/03/200701:00PR Newswire (US)New River Announces Expiration of Hart-Scott-Rodino Waiting PeriodNASDAQ:NRPHNew River Pharmaceuticals (MM)
14/03/200710:30PR Newswire (US)New River Pharmaceuticals Announces Year-End ResultsNASDAQ:NRPHNew River Pharmaceuticals (MM)
24/02/200709:07PR Newswire (US)Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only Stimulant Prodrug VYVANSE(TM) (lisdexamfetamineNASDAQ:NRPHNew River Pharmaceuticals (MM)
20/02/200722:00PR Newswire (US)New River Pharmaceuticals to be Acquired by Shire plc for $64 per ShareNASDAQ:NRPHNew River Pharmaceuticals (MM)
06/02/200702:18PR Newswire (US)New River Pharmaceuticals to Present at 2007 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical ConferenceNASDAQ:NRPHNew River Pharmaceuticals (MM)
26/01/200707:01PR Newswire (US)James Shaffer Joins New River Pharmaceuticals as Vice President, Sales and MarketingNASDAQ:NRPHNew River Pharmaceuticals (MM)
22/12/200615:34PR Newswire (US)New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment ofNASDAQ:NRPHNew River Pharmaceuticals (MM)
22/12/200615:34PR Newswire (US)New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment ofNASDAQ:NRPHNew River Pharmaceuticals (MM)
08/11/200609:22PR Newswire (US)New River Pharmaceuticals Announces Third Quarter 2006 ResultsNASDAQ:NRPHNew River Pharmaceuticals (MM)
31/10/200601:00PR Newswire (US)Interim Results of a Phase III Trial of Lisdexamfetamine Dimesylate (NRP104/LDX) in ADHD Presented at Major Scientific MeetingNASDAQ:NRPHNew River Pharmaceuticals (MM)
13/10/200623:45PR Newswire (US)New River Pharmaceuticals Conducts End-of-Phase II Meeting with FDA for NRP290NASDAQ:NRPHNew River Pharmaceuticals (MM)
07/10/200611:25PR Newswire (US)FDA Issues Approvable Letter for NRP104 (lisdexamfetamine dimesylate) for the Treatment of ADHDNASDAQ:NRPHNew River Pharmaceuticals (MM)
07/10/200611:23PR Newswire (US)New River Pharmaceuticals Inc. Receives Approvable Letter for NRP104NASDAQ:NRPHNew River Pharmaceuticals (MM)
04/10/200607:20PR Newswire (US)Dr. Garen Manvelian Joins New River Pharmaceuticals as Chief Medical OfficerNASDAQ:NRPHNew River Pharmaceuticals (MM)
13/09/200605:00PR Newswire (US)New River Pharmaceuticals Inc. Meets Enrollment in NRP104 Adult Phase III StudyNASDAQ:NRPHNew River Pharmaceuticals (MM)
09/09/200607:38PR Newswire (US)New River Pharmaceuticals to Present at the Bear Stearns 19th Annual Healthcare ConferenceNASDAQ:NRPHNew River Pharmaceuticals (MM)
18/08/200608:03PR Newswire (US)New River Pharmaceuticals Names Dr. Samir Roy Vice President, Formulation and ManufacturingNASDAQ:NRPHNew River Pharmaceuticals (MM)
09/08/200607:46PR Newswire (US)New River Pharmaceuticals Announces Second Quarter 2006 ResultsNASDAQ:NRPHNew River Pharmaceuticals (MM)
26/07/200606:58PR Newswire (US)New River Pharmaceuticals Announces Exercise of Co-Promotion Option in the U.S. for NRP104NASDAQ:NRPHNew River Pharmaceuticals (MM)
26/07/200602:57PR Newswire (US)New River Pharmaceuticals Closes Sale of $135,000,000 Convertible Subordinated NotesNASDAQ:NRPHNew River Pharmaceuticals (MM)
24/07/200623:41Business WireAMRI Announces Long-Term Manufacturing Agreement with New River PharmaceuticalsNASDAQ:NRPHNew River Pharmaceuticals (MM)
20/07/200611:06PR Newswire (US)New River Pharmaceuticals Prices $125 Million Convertible Subordinated Notes; Company to Repurchase Up to $51 million in CommonNASDAQ:NRPHNew River Pharmaceuticals (MM)
19/07/200607:26PR Newswire (US)New River Pharmaceuticals Announces Proposal to Offer $125 Million Convertible Subordinated Notes; Company to Repurchase up toNASDAQ:NRPHNew River Pharmaceuticals (MM)
01/07/200600:31PR Newswire (US)New River Pharmaceuticals Announces Filing of Investigational New Drug Application for NRP409NASDAQ:NRPHNew River Pharmaceuticals (MM)
24/06/200602:52PR Newswire (US)New River Pharmaceuticals to Host Conference Call on A01, A02 and A03 Clinical Abuse Liability Studies of NRP104NASDAQ:NRPHNew River Pharmaceuticals (MM)
21/06/200607:30PR Newswire (US)New River Pharmaceuticals Provides Detail on A02 Clinical Abuse Liability Study of NRP104NASDAQ:NRPHNew River Pharmaceuticals (MM)
19/06/200607:45PR Newswire (US)New River Pharmaceuticals Provides Detail on A01 Clinical Abuse Liability Study and Announces Results from A03 StudyNASDAQ:NRPHNew River Pharmaceuticals (MM)
14/06/200623:01PR Newswire (US)New River Pharmaceuticals to Present Results from NRP104 Abuse Liability StudiesNASDAQ:NRPHNew River Pharmaceuticals (MM)
 Showing the most relevant articles for your search:NASDAQ:NRPH